厄洛替尼联合艾迪注射液在非小细胞肺癌中应用对患者肿瘤标志物及免疫功能的影响

Effect of application of markers and immune function of patients with tumor of erlotinib combined with Addie injection in non-small cell lung cancer

目的:探讨厄洛替尼联合艾迪注射液治疗非小细胞肺癌患者对肿瘤标志物和免疫功能的影响。方法:选取我院因非小细胞肺癌需治疗患者174例,随机分为2组,每组87例,设置为观察组和对照组,观察组予以厄洛替尼联合艾迪注射液,对照组则仅予以厄洛替尼,治疗6周后,比较两组治疗后肿瘤标志物、血管内皮生长因子水平和免疫功能指标。结果:观察组治疗后肿瘤标志物中癌胚抗原(CEA)、糖类抗原19-9(CA199)、细胞角蛋白19片段(CYFRA21-1)和神经元特异性烯醇化酶(NSE)水平低于对照组,差异具有统计学意义(P<0.05);观察组治疗后血管内皮因子-A(VEGFA)、血管内皮因子-B(VEGFB)和血管内皮因子-C(VEGFC)水平低于对照组,差异具有统计学意义(P<0.05);观察组治疗后免疫指标总T淋巴细胞(CD3^+)、辅助T淋巴细胞(CD4^+)、CD4^+/CD8^+水平高于对照组,自然杀伤细胞(NK)水平高于对照组,差异具有统计学意义(P<0.05),观察组治疗后抑制细胞毒T淋巴细胞(CD8^+)水平与对照组持平,差异无统计学意义;观察组治疗后再次免疫反应抗体(IgG)、初次免疫反应抗体(IgM)和粘膜免疫分泌抗体(IgA)水平高于对照组,差异具有统计学意义(P<0.05)。结论:厄洛替尼联合艾迪注射液治疗非小细胞肺癌临床效果较好,可提高免疫功能,降低VEGF和肿瘤标志物水平,推荐临床广泛应用。

Objective： To investigate the efficacy of erlotinib plus Addie injection in the treatment of non-small cell lung cancer patients of tumor markers and immune function. Methods： A total of 174 patients with non-small cell lung cancer who were treated in our hospital from February 2013 to February 2017 were selected and randomly divided into 2 groups： observation group and control group, with 87 cases in each group. The observation group received erlotinib combined with Addie injection and the control group only received erlotinib. After 6 weeks of treatment, tumor markers, vascular endothelial growth factor levels and immune function indexes were compared between the two groups after treatment. Results： CEA （carcinoembryonic antigen）, CA199 （carbohydrate antigen 19-9）, CYFRA21-1 （cytokeratin 19 fragment） and NSE （neuron specific enolase） in tumor markers of the observation group after treatment were lower than those in control group and the difference was statistically significant （ P 〈0.05）. After treatment, the levels of VEGFA （vascular endothelial factor-A）, VEGFB （vascular endothelial factor-B） and VEGFC （vascular endothelial factor-C） in the observation group were lower than those in the control group and the difference was statistically significant （ P 〈0.05）. After treatment, the immune index CD3 ＋ （total T lymphocyte）, CD4 ＋ （helper T lymphocyte） and CD4 ＋/CD8 ＋ levels in the observation group were higher than those in the control group, and the level of NK （natural killer cell） was higher than that of the control group and the difference was statistically significant （P〈0.05）. After treatment, the levels of IgG （re reactive antibody）, IgM （initial immune response antibody） and IgA （mucosal immune secretory antibody） in the observation group were higher than those in the control group and the difference was statistically significant （P〈0.05）. Conclusion： Erlotinib combined with Addie injection in the treatment of non-small cell lung cancer clinical effect is good. It can improve the immune function and reduce the levels of VEGF and tumor markers. It is recommended to be widely used in clinic.